Guidance II Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Guidance II

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: 2MAR$ who wrote (2008)

6/24/2014 10:22:09 PM

From: 2MAR$

of 2077

VRTX Vertex Pharma's Two Phase 3 Studies Meets Primary Endpoint - Quick Facts http://www.rttnews.com/2340790/vertex-pharma-s-two-phase-3-studies-meets-primary-endpoint-quick-facts.aspx?type=ct

Vertex rose 40% this afternoon after the company announced results from a late-stage study combining two Vertex cystic fibrosis drugs, according to Barron's 'Barron's Take' column, which suggested waiting for a lower entry point in the stock as FDA approval in mid-2015 seems priced into the stock. Reference Link :

Citigroup went crazy early with price target of $130

Piper Jaffray believes shares of Vertex are fully valued at current levels after the company reported positive Phase III data. The firm keeps a Neutral rating on the stock with an $87.50 price target.

Summer Street estimates 2019 sales of Kalydeco combo at $3.5B
Following the positive Phase 3 results, Summer Street estimates combo lumacaftor and Kalydeco sales of $3.5B in 2019. The firm has a Neutral rating on shares of Vertex. Vertex price target raised to $107 from $92 at Maxim

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next